Drug Profile
PF 3382792
Alternative Names: PF-03382792Latest Information Update: 02 Oct 2021
Price :
$50
*
At a glance
- Originator Pfizer
- Class
- Mechanism of Action
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Unspecified
Most Recent Events
- 16 Jul 2016 No recent reports of development identified for phase-I development in Undefined in USA (PO)
- 29 Mar 2010 Pfizer completes enrolment in its phase I trial (NCT01045863) in the US
- 03 Mar 2010 Phase-I clinical trials in Undefined indication in USA (PO)